Large-scale real-world data analysis identifies comorbidity patterns in schizophrenia

Chenyue Lu1, Di Jin2, Nathan Palmer1, Kathe Fox1, Isaac S. Kohane1, Jordan W. Smoller3,4 and Kun-Hsing Yu1,5

© The Author(s) 2022

Schizophrenia affects >3.2 million people in the USA. However, its comorbidity patterns have not been systematically characterized in real-world populations. To address this gap, we conducted an observational study using a cohort of 86 million patients in a nationwide health insurance dataset. We identified participants with schizophrenia and those without schizophrenia matched by age, sex, and the first three digits of zip code. For each phenotype encoded in phecodes, we compared their prevalence in schizophrenia patients and the matched non-schizophrenic participants, and we performed subgroup analyses stratified by age and sex. Results show that anxiety, posttraumatic stress disorder, and substance abuse commonly occur in adolescents and young adults prior to schizophrenia diagnoses. Patients aged 60 and above are at higher risks of developing delirium, alcoholism, dementia, pelvic fracture, and osteomyelitis than their matched controls. Type 2 diabetes, sleep apnea, and eating disorders were more prevalent in women prior to schizophrenia diagnosis, whereas acute renal failure, rhabdomyolysis, and developmental delays were found at higher rates in men. Anxiety and obesity are more commonly seen in patients with schizoaffective disorders compared to patients with other types of schizophrenia. Leveraging a large-scale insurance claims dataset, this study identified less-known comorbidity patterns of schizophrenia and confirmed known ones. These comorbidity profiles can guide clinicians and researchers to take heed of early signs of co-occurring diseases.

INTRODUCTION

Schizophrenia is a complex and chronic mental illness accompanied by major impairments in mental and social functioning [1]. It is one of the most disabling psychiatric disorders, affecting >3.2 million individuals in the USA [2] and costing ~$155.7 billion per year [3]. Core symptoms of schizophrenia are categorized as positive, negative, and cognitive symptoms [4]. Positive symptoms are the most easily identified and include hallucinations, delusions, and suspiciousness [5]. Negative symptoms are characterized by deficits of mental or emotional functioning such as impaired attention, avolition, alogia, and anhedonia [6]. Cognitive symptoms involve issues with concentration and memory such as impaired executive function and working memory, and disorganized speech or thoughts [7]. The course of schizophrenia is typically chronic, with only 20% of patients reporting favorable treatment outcomes and the remaining experiencing numerous psychotic episodes and persistent symptoms [5].

Real-world data, such as electronic health records (EHRs) and health insurance claims datasets, are playing an increasingly important role in informing healthcare decisions [8]. These data capture the actual interactions between patients and the healthcare system and provide insights into the clinical courses of individual patients at scale [9]. In the past decade, researchers have developed several population-level phenotype profiling methods based on EHR or health insurance claims data, which enable large-scale analyses of real-world healthcare data. One such effort is the compilation of the phenome-wide association study codes (phecodes), which maps the International Statistical Classification of Diseases and Related Health Problems (ICD) codes to distinct phenotype categories [10, 11]. This effort enables evaluating the associations among a large number of phenotypes and genetic variations [12–14]. Insurance claims datasets provide a rich and unique data source for phenotypical analyses: these datasets contain longitudinal health histories, including drug prescriptions, laboratory tests, procedure codes, and patients’ diagnoses in ICD codes [15], and they comprise millions of patients, enabling large-scale phenome-wide analyses. Population-level phenotypic analyses using phecodes based on insurance claims data have successfully revealed the progression of disease phenotypes in many previous studies [16–22].

A few prior studies examined the common comorbidities of schizophrenia patients [23]. However, these analyses are typically based on small-scale observational studies and clinical trials with up to hundreds of participants [24, 25], and are typically limited in the demographic and geographic diversity of patient cohorts [26]. To address this gap, we leveraged a nationwide health insurance claims dataset from Aetna, which encompassed >86 million participants in the USA, to conduct a population-level study of phenotypes associated with schizophrenia. We conducted data-driven analyses on the patients’ phenotypes before and after the index diagnosis of schizophrenia and compared phenotypic
profiles between schizophrenic patients and matched non-schizophrenic participants. In addition, we systematically compared the phenotypic differences between schizophrenia disorder and other types of schizophrenia. Our systematic analyses enabled the discovery of previously under-reported risk factors and comorbidities of schizophrenia at a population scale.

METHODS
Study participants and dataset summary
Using an identifiable member claims data from Aetna, we identified the International Statistical Classification of Diseases and Related Health Problems (ICD-9 and ICD-10) code profiles of each member. The Aetna dataset contains 86 million participants in total with claims data from January 2008 to December 2019. At the time of participants enrollment in their insurance plans, written informed consent was obtained. This employer-sponsored health insurance includes participants representing all 50 states, the District of Columbia, five populated territories, and Armed Forces Europe, with the most patients from Texas, California, Pennsylvania, Florida, and New York. The dataset records a multitude of patients healthcare-related information, including ICD diagnostic codes, procedures in Current Procedural Terminology (CPT) codes, prescribed drugs in National Drug Codes (NDC), laboratory test results, and basic demographics, such as age and sex. To reduce dimensionality, we mapped each ICD code to its corresponding phecode. Phecodes used in this study are based on both ICD-9 and ICD-10 codes. For example, the phecode 1000 “Burns” contains 388 ICD-9 codes and 3,708 ICD-10 codes related to burns, such as ICD-9 code 940.0 “chemical burn of eyelids and periocular area” and ICD-10 code T23.16 “burn of first degree of back of hand”.

We define schizophrenia patients as participants with at least three occurrences of phecodes 295 and 295.1. Three occurrences were required in determining the presence of schizophrenia to minimize the impact of clinical miscoding, and studies using insurance claims datasets commonly use the same three-hit threshold [27-30]. Patients were included if they had documented birth year, biological sex, and zip code information and had been in the insurance plan for at least 12 months prior to their first diagnosis of schizophrenia. We excluded patients <15 years of age because early-onset schizophrenia is rare and its clinical presentations overlap with developmental and mood disorders, leading to a relatively high level of miscoding in this age group [31]. Each patient in the schizophrenia cohort was matched to a non-schizophrenic control participant of the same birth year, biological sex, and the first three digits of their zip codes. Control participants had no mention of phecodes 295 and 295.1 during their enrollment periods and were enrolled in the claims database at least 1 year prior to their matched patient’s schizophrenia first diagnosis date in the database (the index date). These stringent criteria decrease the uncertainty of clinical conditions extracted from the dataset. Due to the short observation period, we cannot reliably capture the true dates of schizophrenia onset in older adults. Thus, the index date for older participants may represent the date at which schizophrenia resurfaced as an active clinical issue. Harvard Medical School Institutional Review Board approved this study (IRB18-0198).

Systematic analyses of the prevalence of preceding phenotypes of schizophrenia
We conducted comprehensive analyses on each of the 1890 phenotypes defined by the phecodes and reported significantly enriched or depleted phenotypes before the diagnosis of schizophrenia. We focused this analysis on patients whose first schizophrenia documentation occurred between the ages of 15 and 25, because schizophrenia onset usually occurs in the late teens and twenties [32], and given the relatively short observation period of insurance claims datasets, late-onset schizophrenia cases are challenging to ascertain. In identifying the preceding phenotypes, we examined the prevalence of each phecode in the schizophrenic group and the matched control group. To enhance specificity and reduce the impact of coding errors, a phecode was deemed as present only when at least three ICD codes were documented for a given patient. We filtered out phenotypes with <10 patients in either the schizophrenic or the non-schizophrenic group. Fisher’s exact test was performed to evaluate prevalence differences of a phecode of interest between the schizophrenic group and the matched control group. Consistent with standard large-scale systematic studies, we employed one of the more stringent corrections, Bonferroni adjustment, to correct for multiple comparisons of the remaining phenotypes after the filtering steps. We reported the phenotypes predictive of schizophrenia as those with a corrected p-value < 0.05 and ranked them by their odds ratios. We visualized the results with a Manhattan plot using the PheWAS R package, ordered by broader disease categories [33], as well as a volcano plot. Sex-stratified analyses were conducted to identify the phenotypic differences in schizophrenic men and women. To ensure the robustness of the analyses, we filtered out phenotypes with <5 participants in either schizophrenia or non-schizophrenia group. This lower filter threshold of five participants is to account for the smaller sample sizes in the sex-stratified analyses.

Systematic disease risk comparison between schizophrenic and non-schizophrenic groups
To identify the phenotypes occurring after the onset of schizophrenia, we again required a minimum of three codes within a given phecode after the schizophrenia index date. For each phecode analysis, we removed patients who had the phecode within 1 year (the wash-out period) prior to the index date. For patients who did not have the phecode after schizophrenia, their last dates in the database were used as their censored dates. For each phecode, we used univariate Cox proportional hazard models and obtained the hazard ratios and p-values to evaluate the difference between the two patient groups. Phecodes with <10 patients in either the schizophrenic or matched control groups were removed. We reported p-values with Bonferroni-adjusted p-values of <0.05. Sex-stratification analyses were conducted similarly and phenotypes with <5 participants were removed. Additionally, the same analysis was repeated for three different age groups: 15–29, 30–59, as well as 60 and above.

Systematic Disease Risk Comparison between Schizophrenia and Schizoaffective Disorders
The phecodes for schizophrenia capture both schizophrenia and schizoaffective disorder. However, schizoaffective disorder has its own ICD code and diagnostic criteria in the fourth and fifth editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV and DSM-V). To evaluate the phenotypic differences between patients with schizoaffective disorder and those with schizophrenia, we identified ICD codes of schizoaffective disorder and those of schizophrenia without the affective component, and we separated the schizoaffective cohort into patients with schizoaffective disorders and patients with other types of schizophrenia. We removed patients with mentions of both groups and compared the succeeding phecodes of patients in these two groups, because it is difficult to verify their actual diagnoses in this dataset. Phecodes with <5 patients in either the schizoaffective or other schizophrenia groups were removed to mitigate effects from outliers. We reported p-values with Bonferroni-adjusted p-values < 0.05.

RESULTS
Patients characteristics
We identified 61,453 patients with schizophrenia from the insurance claims dataset. Approximately half of the patients (47.2%) were male, consistent with the previously reported population distribution of schizophrenia patients [1]. The average length of patient records in our study cohort is ~6 years. Patients in the cohort represent all 50 states, the District of Columbia, five permanently inhabited territories, and Armed Forces Europe. Supplemental Fig. 1 shows the study flowchart. Details of patient characteristics can be found in Supplemental Table 1 and Supplemental Figs. 2 and 3.

Phenotypes preceding the diagnosis of schizophrenia
To identify the phenotypes preceding a diagnosis of schizophrenia, we identified each of the 1890 phenotypes (P) encoded in the phecodes and counted the number of patients with P in both the schizophrenia patient cohort and the matched control group. Results showed that 144 phecodes are significantly enriched (Bonferroni-corrected P-value < 0.05) in patients who later received schizophrenia diagnoses (Fig. 1), with one phecode enriched in controls. The top ten phenotypes, sorted by odds ratios, enriched in schizophrenic patients are presented in Table 1.
Further stratification by sex revealed that women who later developed schizophrenia are more likely to have type 2 diabetes, obstructive sleep apnea, and eating disorders, while men who later developed schizophrenia are more likely to have conditions such as acute renal failure, developmental delays, and rhabdomyolysis (Supplemental Table 2 and 3).

Data-driven analysis revealed the comorbidities after the onset of schizophrenia

Using a Cox proportional hazard model, we found 402 phenocodes are significantly enriched (Bonferroni-corrected $P$-value $< 0.05$) in the schizophrenic group following the disease onset (Fig. 2), with 24 phenocodes significantly enriched in controls after their index dates. The results are summarized in the Manhattan plot and volcano plot in Fig. 2a, b. Table 2 shows the top ten phenotypes with the highest hazard ratios after the first diagnosis of schizophrenia in the dataset. We tested Cox proportional hazard assumptions using the survminer R package, and only one (316: Substance addiction and disorders) of the top ten phenocodes failed the proportionality assumption after Bonferroni correction of test $p$-values. Sex-stratification analysis shows that women with schizophrenia are more likely to develop encephalopathy, epilepsy, and adverse drug events and allergies, while men with schizophrenia are more likely to develop impulse control disorder, esophageal bleeding, and acute osteomyelitis (Supplemental Tables 4 and 5).

We further investigated disease risks stratified by three age groups: 15–29 years old (adolescents and young adults; 13,828 patients), 30–59 years old ("middle-aged" adults; 16,339 patients), and 60 years old and above (older adults; 31,286 patients).
Table 1. Top ten significantly enriched phenotypes preceding schizophrenia diagnoses in adolescents and young adults aged between 15 and 29 (number of schizophrenia patients in this age group = 13,828).

| Phecode description | Number of schizophrenia patients | Odds ratio | 95% Confidence interval | P-value |
|---------------------|---------------------------------|------------|-------------------------|---------|
| Suicidal ideation   | 775                             | 51.2       | (31.3, 90.2)            | 3 × 10⁻³⁻¹ |
| Bipolar             | 2476                            | 36.1       | (28.0, 45.5)            | 3 × 10⁻⁴⁻⁰ |
| Antisocial/borderline personality disorder | 200 | 18.4 | (10.1, 37.5) | 2 × 10⁻⁴⁻⁰ |
| Substance addiction and disorders | 2635 | 17.6 | (15.1, 20.7) | 2 × 10⁻⁴⁻⁰ |
| Mood disorders      | 1369                            | 17.6       | (15.1, 20.7)            | 5 × 10⁻³⁻⁰ |
| Anxiety, phobic and dissociative disorders | 636 | 16.2 | (8.9, 26.2) | 1 × 10⁻¹⁻⁰ |
| Alcohol-related disorders | 308 | 14.7 | (9.9, 19.6) | 2 × 10⁻¹⁻⁰ |
| Major depressive disorder | 109 | 13.7 | (9.9, 19.6) | 3 × 10⁻¹⁻⁰ |
| Personality disorders | 301 | 13.4 | (9.9, 19.6) | 3 × 10⁻¹⁻⁰ |

We found that substance addiction, anxiety, convulsions, and pain in the limb and neck are frequently reported in schizophrenia patients under 29 years old. Those between 30 and 59 years old tend to develop alcohol-related disorders, posttraumatic stress disorder, gait abnormality, syncope, and chronic kidney disease. Patients over 60 years old suffer from delirium, alcoholism, dementia, sepsis, fracture of the pelvis, osteomyelitis, and hypotension more often than their matched non-schizophrenic participants. (Supplemental Tables 6–8).

Subtypes analysis identified distinct phenotypical patterns between schizophrenia and schizoaffective disorders

Although the standard phecodes for schizophrenia include both schizophrenia and schizoaffective disorder, schizoaffective disorder has distinct diagnostic criteria including a requirement for mood (manic or depressive) episodes. To systematically investigate the phenotypic difference between schizophrenia and schizoaffective disorder after their disease onset, we similarly conducted a data-driven phecode comparison. Of all patients with schizophrenia diagnoses, we obtained 3096 (4.91%) patients who had only schizoaffective disorder and 46,890 (74.4%) who had only schizophrenia or its subtypes. After matching each schizoaffective disorder patient with another patient with other types of schizophrenia of the same age and sex, we compared the succeeding phenotypes in these two groups. After the removal of phecodes with <5 participants in either group, 259 phecodes remained. Fig. 3 and Supplemental Tables 9–10 summarize the differences in succeeding high-risk phenotypes between schizoaffective disorder and schizophrenia.

DISCUSSION

We conducted a large-scale systematic analysis of the comorbidities of schizophrenia using a nationwide health insurance database. Consistent with the literature [34–39], we demonstrated that conditions such as anxiety, posttraumatic stress disorder, as well as alcohol and substance abuse are significantly more common in schizophrenic patients prior to their schizophrenia diagnoses. Benign neoplasm of skin was noted to be more prevalent in non-schizophrenic control patients, suggesting a shared etiology [42] or antipsychotic medications for schizophrenia. According to many related psychiatric disorders, as noted above. In addition, these patients are at higher risk for conditions noted in previous literature, such as senile dementia [40] and epilepsy [41]. Additionally, the risk of eating disorders is enriched after schizophrenia diagnoses, which could stem from either their shared etiology [42] or antipsychotic medications for schizophrenia [43]. Findings from this study could inform clinicians in looking for early signs of these common comorbidities in schizophrenic patients and guide researchers to study the underlying etiology behind the identified comorbidity profiles. We found that men and women with schizophrenia have different comorbidity patterns. For example, women affected by schizophrenia are more likely to develop encephalopathy and adverse drug events, while men with schizophrenia had a higher risk of developing acute osteomyelitis. Our age-stratified analyses showed that, in addition to phenotypes discussed above, adolescents and young adults are likely to develop conduct disorders, insomnia, and...
Depression controls were not significant in schizophrenia. Previous work has developed schizophrenia non-schizophrenia participants have better overall health and a more nuanced diagnoses within the broader category of schizophrenia. By comparing the risk of developing succeeding diseases between patients with schizoaffective disorder and those with other types of schizophrenia, we found significant differences in their comorbidity landscapes. Patients with schizoaffective disorders were at higher risk of developing anxiety disorders, dementia, and obesity. Although hypothyroidism NOS was enriched in patients with schizoaffective disorders, we did not observe such correlation when considering other phecodes related to hypothyroidism. It should also be noted that thyroid
Table 2. Top ten significantly enriched phenotypes after schizophrenia diagnoses overall total number of schizophrenia patients = 61,431.

| Phecode description                  | Number of schizophrenia patients | Hazard ratio 95% Confidence interval | P-value |
|--------------------------------------|----------------------------------|--------------------------------------|---------|
| Coma; stupor; and brain damage       | 1017                             | 87.3 (49.4, 154.2)                   | 2 × 10−53 |
| Altered mental status                | 4334                             | 86.2 (66.1, 112.4)                   | 2 × 10−296 |
| Other conditions of brain            | 1547                             | 75.8 (49.3, 116.6)                   | 2 × 10−96 |
| Alcoholism                           | 5990                             | 60.0 (31.8, 112.4)                   | 2 × 10−308 |
| Bipolar                              | 1151                             | 47.3 (31.8, 70.3)                    | 2 × 10−81 |
| Substance addiction and disorders    | 3181                             | 45.0 (28.8, 55.9)                    | 7 × 10−230 |
| Mood disorders                       | 316                              | 40.2 (28.8, 55.9)                    | 4 × 10−106 |
| Alcohol-related disorders            | 296                              | 32.9 (23.7, 44.7)                    | 1 × 10−85 |
| Posttraumatic stress disorder        | 317                              | 31.2 (23.7, 44.7)                    | 2 × 10−81 |
| Septicemia                           | 300.9                            | 30.4 (20.4, 45.2)                    | 3 × 10−38 |

There are a few limitations in our real-world data analyses. First, this employer-sponsored insurance claims dataset from Aetna only includes patients and their family members and may not represent the general population. Some individuals with schizophrenia are covered by other private insurance, Medicaid, Medicare, or the Veterans Health Administration [48], and thus not included in our dataset. This inherent limitation of our dataset, combined with the fact that we used a conservative definition of schizophrenia (three records or more), was likely responsible for a lower schizophrenia prevalence than the estimate in the general population (0.7%). Second, the follow-up time is relatively short due to the nature of healthcare insurance datasets. Incomplete medical history limited our ability to discover very early signs of schizophrenia. To control for this, we conducted the preceding phenotype analyses only on late teens and young adults (15–29 years of age). In the succeeding phenotype analyses, we required a minimum of 1 year of observation before the index date, during which an eligible patient cannot have an associated schizophrenia code. These enrollment criteria increased the likelihood our index date is the onset date or the day schizophrenia resurfaced as a clinical issue. Third, ICD documentation in claims datasets can be uncertain, noisy, and subject to change over time [49]. For example, despite some overlap in symptoms, bipolar disorder and schizophrenia are mutually exclusive diagnoses based on DSM-V diagnostic criteria. Interestingly, we observed some patients who were initially diagnosed with bipolar disorder later received ICD-codes related to schizophrenia. Prior studies showed that 14.7% of patients receiving bipolar disorder as their initial diagnoses were identified as schizophrenia patients 10 years later [49]. These observations suggest the uncertainties in the initial diagnoses and the noisiness of the diagnostic codes extracted from EHRs. Therefore, cautious interpretation of results from EHR-driven analyses is necessary, and prior knowledge on the disease nosology may distinguish true comorbidities from spurious associations arising from mislabels. To quantitatively mitigate the uncertainty and noisiness of ICD coding, we applied a more stringent threshold for our inclusion criteria, requiring a minimum of three documented diagnoses. Our use of Bonferroni correction further decreases false-positive findings; lending improved reliability to our data-driven analyses. Lastly, although phecodes reduce the noise from inconsistent coding in different hospital systems and curtail its impact on our analyses, they only represent coarse categories of clinical phenotypes. For example, specific phenotypes within eating disorders (phecode: 305.2) have distinct etiologies and clinical presentations. Conditions such as bulimia nervosa, psychogenic loss of appetite, and cyclical vomiting are all categorized as eating disorders, obscuring more detailed clinical information. Future studies of EHR data examining individual ICD codes and incorporating natural language processing of the unstructured clinical notes could facilitate the characterization of more granular phenotypes.
Future research can further validate our findings in other large survey or registry databases [50, 51]. As an illustration, our systematic analyses revealed that obstructive sleep apnea is an enriched phenotype preceding the schizophrenia diagnoses in female patients. We hypothesize this finding is related to the connections among overweight, schizophrenia, and psychotropic medication [52]. These identified comorbidity patterns from our systematic analyses can help inform individualized predictive models for the onset of schizophrenia and its comorbidities [53]. Future studies can identify the causal genetic pathways, environmental mediators, or drug effects underpinning the observed associations. For example, studies have observed shared genetic risk between schizophrenia and immune-related disorders [54, 55]. As such, the identified correlations between schizophrenia and infections in this dataset may be partially explained by genetic predispositions.

In summary, our real-world data analyses revealed the common preceding and succeeding phenotypes of schizophrenia. We showed that psychiatric disorders, such as posttraumatic stress disorder and anxiety often precede and succeed the onset or new diagnosis of schizophrenia. Additionally, conduct disorders, eating disorders, and insomnia commonly followed schizophrenia onset among adolescents and young adults, and dementia and osteomyelitis occurred after older adults had a new diagnosis of schizophrenia. Such information could guide clinicians and researchers to look out for early signals and co-occurring diseases of schizophrenia in different age and sex groups, in order to help their patients better manage these illnesses.

**DATA AVAILABILITY**

The codes for conducting the analyses and the raw result tables could be found on a public GitHub repository: https://github.com/hms-dbmi/schizophrenia_comorbidity.

**REFERENCES**

1. Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician. 2007;75:1821–9.
2. Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. Pharm Therapeutics. 2014;39:638.
3. Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Katam SA, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77:764–71.
4. Crismon, L, Argo, TR & Buckley, PF. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill; 2014.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. San Francisco: American Psychiatric Association; 2013.
6. Bagney A, Rodriguez-Jimenez R, Martinez-Gras L, Sanchez-Morla EM, Santos JL, Jimenez-Arriero MA, et al. Negative symptoms and executive function in schizophrenia: does their relationship change with illness duration? Psychopathology. 2013;46:241–8.
7. Thaker GK. Defining the schizophrenia phenotype. Curr psychiatry Rep. 2000;2:398–403.
8. Beaulieu-Jones BK, Finlayson SG, Yuan W, Altman RB, Kohane IS, Prasad YV, et al. Examining the use of real-world evidence in the regulatory process. Clin Pharmacol Therapeutics. 2020;107:843–52.
9. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—what is it and what can it tell us. N Engl J Med. 2016;375:2293–7.
10. Denny JC, Ritchie MD, Basaraba IA, Pullen JM, Bastarache L, Brown-Gentry K, et al. Phenome-wide association studies as a tool to advance precision medicine. Annu Rev Genomics Hum Genet. 2016;17:353–73.
11. Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome-phenome relationship using phenome-wide association studies. Nat Rev Genet. 2016;17:129–45.
12. Li Z, Gaudreau N, Arsenault BJ, Mathieu P, Bosse Y, Theriault S. Phenome-wide analyses establish a specific association between aortic valve PALMD expression and calcific aortic valve stenosis. Commun Biol. 2020;3:477.
13. Zhang, T, Goodman, M, Zhu, F, Healy, B, Carruthers, R, Chinonis, T et al. Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. Neural Immunomunol Neuroinflamm. 2020. https://doi.org/10.1212/NXI.0000000000000864.
14. Hebbing SJ. The challenges, advantages and future of phenome-wide association studies. Immunology. 2014;141:157–65.
15. Pendergrass S, Brown-Gentry K, Dudek S, Torterson E, Ambite J, Avery C, et al. The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery. Genet Epidemiol. 2011;35:410–22.
16. Namjou B, Marsolo K, Carroll RJ, Denny JC, Ritchie MD, Verma SS, et al. Phenome-Wide Association Study (PheWAS) in EMR-linked pediatric cohorts, genetically links PLCL1 to speech language development and IL5-IL13 to Eosinophilic esophagitis. Front Genet. 2014;5:401
17. Robinson JR, Denny JC, Roden DM, Driest SL. Genome-wide and phenome-wide approaches to understand variable drug actions in electronic health records. Clin Transl Sci. 2017;11:112–12.
18. Pillai, DP. Clinical trend discovery and analysis of Taiwanese health insurance claims data. MA: Massachusetts Institute of Technology; 2016.
19. Martin-Sanchez F, Aguilar-Pulido V, Lopez-Campos G, Peek N, Sacchi L. Secondary use and analysis of big data collected for patient care. Yearb Med Inform. 2017;26:28–37.
21. Yu K-H, Miron O, Palmer N, Lemos DR, Fox K, Kou S, et al. Data-driven analyses revealed the comorbidity landscape of tuberous sclerosis complex. Neurology. 2018;91:974–6.

22. Yu KH, Palmer N, Fox K, Prock L, Mandl K, Kohane I, et al. The phenotypical implications of immune dysregulation in fragile X syndrome. Eur J Neurol. 2020;27:590–3.

23. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35:383–402.

24. Ivata Y, Nakajima S, Suzuki T, Keefe R, Piltnan E, Chung J, et al. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Mol psychiatry. 2015;20:1151–60.

25. Kulkarni J, Gavrilidis E, Wang W, Worley R, Fitzgerald G, Gurvich C, et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol psychiatry. 2015;20:695–702.

26. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med. 2006;21:1133–7.

27. Fereci, AG, Uppal, N, Gutierrez-Sacristan, A, Mousavi, S, Greenspun, P, Surati, R, et al. Medication use in the management of comorbidities among individuals with autism spectrum disorder from a large nationwide insurance database. JAMA Pediatr. 2021. https://doi.org/10.1001/jamapediatrics.2021.1329.

28. Kalinich, M, Murphy, W, Wongvibulsin, S, Pahalyants, V, Yu, KH, Lu, C et al. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J Immunother Cancer. 2021. https://doi.org/10.1136/jitc-2020-001935.

29. Yang S, Yu KH, Palmer N, Fox K, Kou SC, Kohane IS. Autoimmune effects of lung cancer immunotherapy revealed by data-driven analysis on a nationwide cohort. Clin Pharm Ther. 2020;107:388–96.

30. Wang F, Yang S, Palmer N, Fox K, Kohane IS, Liao KP, et al. Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types. NPJ Precis Oncol. 2021;5:1–11.

31. McClellan J, Werry J. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2001;40:45–235.

32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR. San Francisco: American Psychiatric Association; 2000.

33. Carroll RJ, Bastarache L, Denny JC, R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics. 2014;40:2375–6.

34. Laursen TM, Agerbo E, Pedersen CB. Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index. J Clin Psychiatry. 2009;70:1432–8.

35. Ventriglio A, Gentile A, Bonfitto I, Stella E, Mari M, Steardo L, et al. Suicide in the Early Stage of Schizophrenia. Front Psychiatry. 2016;7:116.

36. Fuller-Thomson E, Hollister B. Schizophrenia and suicide attempts: a representative community-based Canadian sample. Schizophr Res Treat. 2016;2016:3165243.

37. Radomsky ED, Haas GL, Mann JJ, Sweeney JA. Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am J Psychiatry. 1999;156:1590–5.

38. Zheng Z, Zheng P, Zou X. Association between schizophrenia and autoimmune spectrum disorder: a systematic review and meta-analysis. Autism Res. 2018;11:1110–9.

39. Dickey B, Azeni H, Weiss R, Sederer L. Schizophrenia, substance use disorders and medical co-morbidity. J Ment Health Policy Econ. 2000;3:27–33.

40. de Vries PJ, Honer WG, Kemp PM, McKenna PJ. Dementia as a complication of schizophrenia. J Neurol, Neurosurg, Psychiatry. 2001;70:588–96.

41. Cascella NG, Schretlen DJ, Sawa A. Schizophrenia and epilepsy: is there a shared susceptibility? Neurosci Res. 2009;63:227–35.

42. Morylowksa-Topolisa J, Zieminski M, Molas A, Gajewski J, Flis M, Stelmach E, et al. Schizophrenia and anorexia nervosa - reciprocal relationships. A literature review. Psychiatr Pol. 2017;51:261–70.

43. Sentissi O, Wala A, Bourdel MC, Kaminiski F, Bellisle F, Olie JP, et al. Impact of ankyrsyptic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients. Int Clin Psychopharmacol. 2009;24:257–64.

44. Carter JW, Schulsinger F, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35:383–402.

45. Heinrich TW, Graham G. Hypothyroidism presenting as psychosis: myxedema madness revisited. Prim Care Companion J Clin Psychiatry. 2003;5:260–6.

46. Malapsina D, Owen MJ, Heckers S, Tandon R, Bustillo J, Schultz S, et al. Schizo-affective disorder in the DSM-5. Schizophr Res. 2013;150:21–25.

ACKNOWLEDGEMENTS

The authors thank Dr. Nils Gehlenborg for helpful suggestions and Erica Meyer for providing assistance with data access. This study is supported in part by the National Institute of General Medical Sciences (NIGMS) grant R35GM143879 and the Blavatnik Center for Computational Biomedicine Award.

AUTHOR CONTRIBUTIONS

This study was conceptualized by CL, D.J., and K-H.Y. Analytical methodology was developed by CL, D.J., and K-H.Y. The data was curated by N.P. and K.F. Formal analyses were conducted by CL and D.J. with supervision by K-H.Y. The manuscript was drafted by C.L. and D.J., and N.P., K.F., I.S.K., J.W.S., and K.-H.Y. revised the manuscript. Funding was acquired by K-H.Y.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1383/s41398-022-01916-y.

Correspondence and requests for materials should be addressed to Kun-Hsing Yu.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022